Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity

References

• Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg’s Arch Pharmacol 2004;369:78–88
   Google Scholar
• La Du BN, Aviram N, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119–120:379–88
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Scherer SW, Xi T, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998;213:149–57
   PubMed Web of Science ®Google Scholar
• Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412–19
   PubMed Web of Science ®Google Scholar
• Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol 2003;66:887–96
   PubMed Web of Science ®Google Scholar
• Gan KN, Smolen A, Eckersen HW, La Du BN. Purification of human serum paraoksonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100–6
   PubMed Web of Science ®Google Scholar
• Costa LG, Furlong CE. Paraoxonase. Norwell (MA): Kluwer Academic Publishers; 2002
   Google Scholar
• Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;3:371–92
   Google Scholar
• Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334–6
   PubMed Web of Science ®Google Scholar
• Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335–41
   PubMed Web of Science ®Google Scholar
• Tougou K, Nakamura A, Watanabe S, et al. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998;26:355–9
   PubMed Web of Science ®Google Scholar
• Biggadike K, Angell RM, Burgess CM, et al. Selective plasma hydrolysis of glucocorticoidg-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem 2000;43:19–21
   PubMed Web of Science ®Google Scholar
• Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541–50
   PubMed Web of Science ®Google Scholar
• Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON1 by fenofibrate and statins. Mol Pharmacol 2003;63:945–56
   PubMed Web of Science ®Google Scholar
• Kiranoglu S, Sinan S, Gencer N, et al. In vivo effects of oral contraceptives on paraoxonase, catalase and carbonic anhydrase enzyme activities on mouse. Biol Pharm Bull 2007;30:1048–51
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochime 2006;88:565–74
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Gencer N, et al. Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro. Biochemistry (Moscow) 2006;71:46–50
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–5
   PubMed Web of Science ®Google Scholar
• Li H, Horke S, Förstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 2013;34:313–9
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Med 2012;54:83–90
   PubMed Web of Science ®Google Scholar
• Eren E, Yilmaz N, Aydin O. Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis. Cholesterol 2013;2013:792090
   PubMedGoogle Scholar
• Kockar F, Sinan S, Yildirim H, Arslan O. Differential effects of some antibiotics on paraoxonase enzyme activity on human hepatoma cells (HepG2) in vitro. J Enzyme Inhib Med Chem 2010;25:715–9
   PubMed Web of Science ®Google Scholar
• Ozensoy Guler O, Arslan O, Kockar F. Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII. Methods Find Exp Clin Pharmacol 2008;30:335–40
   Google Scholar
• Ozensoy O, Arslan O, Kockar F. Differential in vitro inhibition effects of some antibiotics on tumor associated carbonic anhydrase isozymes of hCA-IX and hCA-XII. J Enzyme Inhib Med Chem 2008;23:579–85
   PubMed Web of Science ®Google Scholar
• Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337–44
   PubMed Web of Science ®Google Scholar
• Mirdamadi HZ, Sztanek F, Derdak Z, et al. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008;66:366–73
   PubMed Web of Science ®Google Scholar
• Kassai A, Illyes L, Mirdamadi HZ, et al. The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2007;40:1–5
   PubMed Web of Science ®Google Scholar
• Paragh G, Seres I, Harangi M, et al. Ciprofibrate increases paraoxonase activity in patients with metabolic syn-drome. Br J Clin Pharmacol 2006;61:694–701
   Google Scholar
• Kurban S, Mehmetoglu I. Effects of acetylsalicylic acid on serum paraoxonase activity, ox-LDL, coenzyme Q 10 and other oxidative stress markers in human volunteers. Clin Biochem 2010;43:287–90
   PubMed Web of Science ®Google Scholar
• Van Wijk J, Coll B, Castro Cabezas M, et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 2006;33:1134–7
   PubMedGoogle Scholar
• Deakin S, Leviev I, Guernier S, James RW. Statin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol regulatory element binding protein 2. Arterioscler Thromb Vasc Biol 2003;23:2083–9
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozilmetabolites, but not the parent drugs, are potent antioxidants againstlipoprotein oxidation. Atherosclerosis 1998;138:271–80
   PubMed Web of Science ®Google Scholar
• Turay J, Grniakova V, Valka J. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate. Drugs Exp Clin Res 2000;26:83–8
   PubMedGoogle Scholar
• Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998;138:217–25
   PubMed Web of Science ®Google Scholar
• Blatter-Garin MC, Kalix B, De Pree S, James RW. Aspirin use is associated with higher serum concentrations of the antioxidant enzyme, paraoxonase-1. Diabetologia 2003;46:593–4
   PubMed Web of Science ®Google Scholar
• Ahmad S, Carter JJ, Scott JE. A homogenous cell-based assay for measurement of endogenous paraoxonase activity. Anal Biochem 2010;400:1–9
   Google Scholar
• Wojcicka G, Jamroz-Wisniewska A, Marciniak A, et al. The differentiating effect of glimepiride and glibenclamide on paraoxonase-1 and platelet-activating factor acetylohydrolase. Life Sci 2010;87:126–32
   Google Scholar
• Sinan S, Kockar F, Gencer N, et al. Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull 2006;29:1559–63
   PubMed Web of Science ®Google Scholar
• Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug ınteractions. Psychosomatics 2005;46:464–94
   PubMed Web of Science ®Google Scholar